Edition:
United States

VIVUS Inc (VVUS.O)

VVUS.O on Nasdaq

1.09USD
17 Feb 2017
Change (% chg)

$0.01 (+0.93%)
Prev Close
$1.08
Open
$1.09
Day's High
$1.12
Day's Low
$1.08
Volume
324,651
Avg. Vol
443,862
52-wk High
$1.85
52-wk Low
$0.93

VVUS.O

Chart for VVUS.O

About

VIVUS, Inc. is a biopharmaceutical company. The Company operates in the development and commercialization of therapeutic products segment. It provides over two therapies approved by the Food and Drug Association (FDA), which include Qsymia (phentermine and topiramate extended-release) for chronic weight management and STENDRA... (more)

Overall

Beta: 0.72
Market Cap(Mil.): $114.28
Shares Outstanding(Mil.): 104.84
Dividend: --
Yield (%): --

Financials

  VVUS.O Industry Sector
P/E (TTM): -- 28.47 29.39
EPS (TTM): -0.44 -- --
ROI: -21.11 13.57 13.06
ROE: -- 14.45 14.19

BRIEF-Vivus entered into settlement agreement with Hetero on Jan. 3

* On Jan 3, co entered into a settlement agreement with hetero - sec filing

Jan 09 2017

BRIEF-Vivus and Selten Pharma announce agreement for development and commercialization rights to treatments for PAH

* Vivus and Selten Pharma announce agreement for the development and commercialization rights to treatments for Pulmonary Arterial Hypertension (PAH)

Jan 09 2017

BRIEF-Vivus reports Q3 net loss per share $0.09

* Qtrly total revenue $13.4 million versus $24.9 million Source text for Eikon: Further company coverage:

Nov 09 2016

BRIEF-Vivus and Metuchen Pharmaceuticals announce license agreement for commercial rights to Stendra

* VIVUS Inc says additionally, Metuchen will be responsible for royalties due to Mitsubishi Tanabe Pharma corporation based on net sales

Oct 03 2016

BRIEF-Vivus says extends return date of Stendra commercial rights

* Vivus inc says extends return date of stendra commercial rights

Aug 29 2016

More From Around the Web

Earnings vs. Estimates